Bristol Myers Squibb Company $BMY Shares Bought by First Trust Advisors LP

First Trust Advisors LP raised its position in Bristol Myers Squibb Company (NYSE:BMY) by 4.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,534,556 shares of the biopharmaceutical company’s stock after buying an additional 243,511 shares during the quarter. First Trust Advisors LP’s holdings in Bristol Myers Squibb were worth $335,671,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Swiss RE Ltd. purchased a new stake in Bristol Myers Squibb in the 4th quarter valued at $25,000. Darwin Wealth Management LLC purchased a new position in Bristol Myers Squibb during the 2nd quarter worth $25,000. Physician Wealth Advisors Inc. grew its position in Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares during the last quarter. Bayban acquired a new position in Bristol Myers Squibb in the fourth quarter valued at $31,000. Finally, EQ Wealth Advisors LLC acquired a new position in Bristol Myers Squibb in the fourth quarter valued at $32,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol Myers Squibb Trading Up 1.2%

Shares of BMY stock opened at $60.89 on Wednesday. The business’s fifty day moving average price is $57.20 and its 200 day moving average price is $57.90. The firm has a market capitalization of $124.34 billion, a PE ratio of 17.10, a P/E/G ratio of 0.17 and a beta of 0.23. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. During the same quarter last year, the company earned $1.80 earnings per share. Bristol Myers Squibb’s quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts forecast that Bristol Myers Squibb Company will post 6.34 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%. Bristol Myers Squibb’s payout ratio is currently 70.79%.

Analyst Ratings Changes

Several brokerages have recently weighed in on BMY. Bank of America decreased their target price on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research note on Friday, July 10th. Guggenheim reaffirmed a “buy” rating and set a $72.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $54.00 price objective on shares of Bristol Myers Squibb in a research report on Monday, July 6th. UBS Group reiterated a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Finally, Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $61.25.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb expanded its NVIDIA collaboration and plans to deploy a next-generation DGX SuperPOD AI system to speed drug discovery, a potentially positive long-term productivity and innovation catalyst. Article Title
• Positive Sentiment: The company said it will be the first life sciences firm to buy NVIDIA’s DGX SuperPOD based on Vera Rubin systems, highlighting an aggressive push into advanced AI infrastructure for drug development. Article Title
• Positive Sentiment: Bristol Myers is also being viewed as a peer in next-generation cancer treatment innovation, with its bispecific antibody work alongside BioNTech mentioned in coverage of therapies that could help replace older blockbuster drugs over time. Article Title
• Neutral Sentiment: Healthcare stocks traded lower late Monday afternoon, which could have offset some of the positive company-specific momentum in BMY. Article Title

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.